Skip to main content
Delfa

← All assets

ELND005

4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

4

Ongoing

0

Recruiting

0

Completed

4

Sites

136

Countries

4

Endpoints

36

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 36 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
4

Trials by status

Completed
4

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
12
Behavior / neuropsychiatric
10
Function / daily living
6
Safety / tolerability / PK
6
Other (unclassified)
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 20 of 36 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Neuropsychiatric Inventory (NPI)Behavior

8

ADCS-Activities of Daily Living (ADCS-ADL)Function

6

ADAS-CogCognition

2

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

2

Mini-Mental State Examination (MMSE)Cognition

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

4 of 4

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT01735630Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

ELND005

Alzheimer’s disease

Alzheimer's diseasePh 2Completed70May 2015-results
NCT00568776ELND005 in Patients With Mild to Moderate Alzheimer's Disease

ELND005

Alzheimer’s disease

Alzheimer's diseasePh 2Completed62May 2010-results
NCT00934050ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease

ELND005

Alzheimer’s disease

-Ph 2Completed38Jun 2011-results
DS201A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia

ELND005

Mixed / unspecified dementia

Age 18-45Ph 2Completed3Jun 20141results

Showing 1-4 of 4 trials